within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC05_Gemcitabine;

model Gemcitabine
  extends Pharmacolibrary.Drugs.ATC.L.L01BC05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01BC05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gemcitabine is a nucleoside analog used as an antineoplastic (anticancer) agent. It is approved and widely used for treatment of various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and breast cancer. It works primarily by inhibiting DNA synthesis, leading to cell death.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (both sexes), typically aged 18-80 years, receiving intravenous infusion of gemcitabine. No major differences were observed based on sex or cancer type.</p><h4>References</h4><ol><li><p>Thompson, BR, et al., &amp; Smith, DE (2020). Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. <i>Biochemical pharmacology</i> 180 114127–None. DOI:<a href=\"https://doi.org/10.1016/j.bcp.2020.114127\">10.1016/j.bcp.2020.114127</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32603666/\">https://pubmed.ncbi.nlm.nih.gov/32603666</a></p></li><li><p>Alharbi, AF, et al., &amp; Kirstein, MN (2019). Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. <i>Cancer chemotherapy and pharmacology</i> 83(2) 387–391. DOI:<a href=\"https://doi.org/10.1007/s00280-018-3757-7\">10.1007/s00280-018-3757-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30542769/\">https://pubmed.ncbi.nlm.nih.gov/30542769</a></p></li><li><p>Freise, KJ, &amp; Martín-Jiménez, T (2006). Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. <i>Journal of veterinary pharmacology and therapeutics</i> 29(2) 147–152. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.2006.00726.x\">10.1111/j.1365-2885.2006.00726.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16515669/\">https://pubmed.ncbi.nlm.nih.gov/16515669</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Gemcitabine;
